Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: Results from a prospective feasibility study [1]

Lung Cancer

Volumn 50, Issue 3, 2005, Pages 413-415

  Hotta, Katsuyuki ^a   Inoue, Akira ^b   Kiura, Katsuyuki ^a   Ueoka, Hiroshi ^a   Tanimoto, Mitsune ^a   Nukiwa, Toshihiro ^b  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GEFITINIB;

BLOOD TOXICITY; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEMORRHAGIC CYSTITIS; HUMAN; LETTER; LUNG INFILTRATE; LUNG NON SMALL CELL CANCER; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CYSTITIS; FEASIBILITY STUDIES; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PNEUMONIA; QUINAZOLINES; VOMITING;

EID: 33644550293     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2005.07.006     Document Type: Letter

References (6)

1. K. Fujiwara, K. Kiura, H. Ueoka, M. Tabata, S. Hamasaki, and M. Tanimoto Dramatic effect of ZD 1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status Lung Cancer 40 2003 73 76
2. R. Zinner, R. Govindan, A.J. Wozniak, J.L. Wade, C.P. Belani, and C.D. Thienelt Compassionate use experience with gefitinib in poor performancePS) patients with advanced non-small-cell lung cancer (NSCLC) treated in an expanded access program (EAP) Proc Am Soc Clin Oncol 23 2004 633 abstr 7082
3. N.R. Dickson, J.D. Hainsworth, D.R. Spigel, H.A. Burris, D.A. Yardley, and M. Thomas Single agent gefitinib in poor performance status patients with previously untreated advanced non-small cell lung cancer: A Minnie Pearl Cancer Research Network phase II trial Proc Am Soc Clin Oncol 23 2004 634 abstr 7086
4. C. Gridelli, P. Maione, V. Castaldo, and A. Rossi Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer Br J Cancer 89 2003 1827 1829
5. G.C. Chang, K.C. Chen, T.Y. Yang, M.C. Yin, C.P. Lin, and B. Kuo Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status Invest New Drugs 23 2005 73 77
6. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, and B.W. Brannigan Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139